Alembic Pharmaceuticals Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|
| Revenue | 1,583.85 | 1,421.55 | 1,609.28 |
| Operating Expense | 1,399.98 | 1,226.26 | 1,320.86 |
| Net Profit | 75.34 | 85.81 | 165.78 |
| Net Profit Margin | 4.76 | 6.04 | 10.30 |
| Earning Per Share | 3.83 | 4.37 | 8.43 |
| EBIDTA | 183.87 | 195.29 | 288.42 |
| Effective Tax Rate | 8.82 | 9.22 | 11.87 |
| Particulars | Mar 2025 |
|---|---|
| Revenue | 1583.85 |
| Operating Expense | 1399.98 |
| Net Profit | 75.34 |
| Net Profit Margin | 4.76 |
| Earning Per Share | 3.83 |
| EBIDTA | 183.87 |
| Effective Tax Rate | 8.82 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Total Revenue Annual | 6,032.63 | 5,874.06 | 5,149 |
| Operating Expenses Annual | 5,131.24 | 4,875.54 | 4,484.66 |
| Operating Profit Annual | 962.14 | 1,029.84 | 667.88 |
| Interest Annual | 76.47 | 54.47 | 49 |
| Depreciation | 277.08 | 271.14 | 272.95 |
| Net Profit Annual | 503.12 | 666.48 | 346.73 |
| Tax Annual | 105.47 | 37.75 | -0.80 |
| Particulars | Mar 2025 |
|---|---|
| Total Revenue Annual | 6,032.63 |
| Operating Expenses Annual | 5,131.24 |
| Operating Profit Annual | 962.14 |
| Interest Annual | 76.47 |
| Depreciation | 277.08 |
| Net Profit Annual | 503.12 |
| Tax Annual | 105.47 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Cash Flow at the Beginning | 20.13 | 21.67 | 13.56 |
| Cash Flow from Operations | 226.55 | 772.77 | 730.25 |
| Cash Flow from Investing | -636.06 | -329.02 | -460.98 |
| Cash Flow from Financing | 403.61 | -445.29 | -261.16 |
| Cash Flow at the End | 14.23 | 20.13 | 21.67 |
| Particulars | Mar 2025 |
|---|---|
| Cash Flow at the Beginning | 20.13 |
| Cash Flow from Operations | 226.55 |
| Cash Flow from Investing | -636.06 |
| Cash Flow from Financing | 403.61 |
| Cash Flow at the End | 14.23 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| PBDIT Margin (%) | 15.95 | 17.53 | 12.97 |
| PBIT Margin (%) | 11.36 | 12.92 | 7.67 |
| PBT Margin (%) | 11.21 | 12.68 | 7.51 |
| Net PROFIT Margin (%) | 8.34 | 11.35 | 6.73 |
| Return On Networth / Equity (%) | 9.96 | 14.30 | 7.15 |
| Return On Networth /Employed (%) | 11.40 | 14.13 | 6.98 |
| Return On Assets (%) | 8.34 | 12.37 | 6.13 |
| Total Debt / Equity (X) | 0.17 | 0.13 | 0.15 |
| Asset Turnover Ratio (%) | 1 | 1.09 | 0.91 |
| Particulars | Mar 2025 |
|---|---|
| PBDIT Margin (%) | 15.95 |
| PBIT Margin (%) | 11.36 |
| PBT Margin (%) | 11.21 |
| Net PROFIT Margin (%) | 8.34 |
| Return On Networth / Equity (%) | 9.96 |
| Return On Networth /Employed (%) | 11.40 |
| Return On Assets (%) | 8.34 |
| Total Debt / Equity (X) | 0.17 |
| Asset Turnover Ratio (%) | 1 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Fixed Assets Annual | 2,513.47 | 2,535.66 | 2,377.45 |
| Total Current Assets Annual | 3,766.20 | 2,988.56 | 2,780.22 |
| Non Current Assets Annual | 3,790.07 | 3,409.99 | 3,350.20 |
| Total Shareholders Funds Annual | 5,194.74 | 4,908.91 | 4,414.30 |
| Total Assets Annual | 7,556.27 | 6,398.55 | 6,130.42 |
| Particulars | Mar 2025 |
|---|---|
| Fixed Assets Annual | 2,513.47 |
| Total Current Assets Annual | 3,766.20 |
| Non Current Assets Annual | 3,790.07 |
| Total Shareholders Funds Annual | 5,194.74 |
| Total Assets Annual | 7,556.27 |
EPS (INR)
Expected
7.98
Reported
7.98
Surprise
0.00%
Dec 2024
EPS beaten by 0.00%
Sep 2024
EPS beaten by -0.43%
Jun 2024
EPS beaten by -0.26%
